Business
Immuneering Strengthens Board of Directors with the Appointment of Diana F. Hausman, M.D.
Industry Executive Brings More than 20 Years of Clinical Drug Development Expertise CAMBRIDGE, Mass., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Immuneering
About this update from Immuneering Corporation
[{"type":"text","content":"Industry Executive Brings More than 20 Years of Clinical Drug Development Expertise\nCAMBRIDGE, Mass., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates that are designed to uniquely disrupt cellular signaling dynamics, today announced the appointment of Diana F. Hausman, M.D., Chief Medical Officer of Lengo Therapeutics (a wholly-owned subsidiary of Blueprint Medicines Corporation), to its Board of Directors. This appointment brings Immuneering’s Board to six members. “Diana has dedicated her career to creating new and better possibilities for cancer patients, as a Board certified oncologist with more than 20 years of clinical drug development experience at both privately held and publicly traded companies. She brings an important depth of expertise which will be invaluable as we continue to advance our pipeline including our lead candidate, IMM-1-104, a dual-MEK inhibitor for the treatment of RAS mutant solid tumors,” stated Ben Zeskind, Ph.D., Co-Founder and Chief Executive Officer of Immuneering. “She will fit right in with our phenomenal, world-class board and her strengths will be highly complementary. We look forward to Diana’s many contributions.” “The preclinical data for IMM-1-104 is highly compelling, and supports Immuneering’s unique deep-cyclic inhibition approach for treating the many tumors that are driven by MAPK pathway activation,” noted Dr. Hausman. “The earlier stage pipeline is also very exciting, along with the translational bioinformatics platform that yielded many of the counterintuitive, data-driven insights underlying these programs. The Immuneering team is terrific. I am honored to be working with them, and am eager to bring my specific skills, insights and industry relationships to bear in order to help the company achieve its goals.” Dr. Hausman’s broad pharmaceutical industry experience includes work with biologics, antibody-drug conjugates and targeted small molecules in the fields of oncology (including immunotherapy), hemostasis, hepatitis C, and Crohn's disease. Additionally, she is well versed in all aspects of drug development, including development and implementation of clinical strategy. Since June 2021, Dr. Hausman has been the Chief Medical Officer of Lengo Therap...